Dodecafluoropentane Improves Neurological Function Following Anterior Ischemic Stroke.

Area of Science:

• Neuroscience
• Biomedical Engineering
• Pharmacology

Background:

• Cerebral ischemia poses a significant threat, necessitating advanced treatments like oxygen transport drugs.
• Dodecafluoropentane emulsion (DDFPe) has shown promise in maintaining brain tissue viability during ischemic events.
• Previous studies established DDFPe's efficacy in standard anterior stroke models (STND) with 90-minute intervals.

Purpose of the Study:

• To investigate the efficacy of shortened DDFPe dosage schedules (30 or 60-minute intervals) in nonstandard posterior (NSTND) ischemic stroke models.
• To determine if more frequent DDFPe administration improves neurological outcomes, reduces stroke volume, and lowers serum glutamate levels in NSTND strokes.
• To compare DDFPe's effectiveness in anterior versus posterior cerebral artery stroke models under accelerated dosing regimens.

Main Methods:

• New Zealand White rabbits (N=26) were subjected to embolization to induce STND or NSTND strokes.
• Animals were randomized into control (saline) and DDFPe treatment groups (30-min or 60-min intervals).
• Neurological assessments, serum glutamate level measurements, and post-mortem stroke volume quantification (%SV) were performed.

Main Results:

• In DDFPe-treated STND groups, a significant reduction in %SV, neurological assessment scores (NAS), and serum glutamate was observed compared to controls (p < 0.05).
• In contrast, DDFPe treatment in NSTND groups showed no statistically significant differences in %SV, NAS, or serum glutamate compared to NSTND controls (p > 0.05).
• Accelerated DDFPe dosage schedules (30 or 60-min intervals) did not yield additional benefits over standard intervals in either stroke model.

Conclusions:

• Dodecafluoropentane emulsion (DDFPe) demonstrates therapeutic benefits in anterior cerebral artery ischemic strokes.
• DDFPe is less effective in mitigating damage and improving outcomes in more severe posterior cerebral artery ischemic strokes, even with intensified dosing.
• The study suggests that stroke severity and location significantly influence the therapeutic potential of DDFPe, highlighting the need for model-specific treatment strategies.